Teva will “defend itself vigorously” and continue to work with the European Commission to seek a resolution, though a spokesperson warned the process could “take several years.” (Photo by THOMAS ...
Teva Pharmaceutical Industries ($TEVA) is facing whistleblower allegations that it used kickbacks, disguised as speaking fees, to persuade doctors to boost ...
Mylan’s long-awaited rival for Teva’s blockbuster multiple sclerosis drug Copaxone has been approved in the US, putting a large chunk of the Israeli firm’s revenues at risk. The timing could not have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results